Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
暂无分享,去创建一个
Marcel de Matas | Henry Chrystyn | H. Chrystyn | Q. Shao | M. de Matas | Qun Shao | Catherine H Richardson | C. H. Richardson
[1] K. Brown,et al. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[2] H. Chrystyn,et al. Determination of the relative bioavailability of salbutamol to the lung following inhalation. , 1992, British journal of clinical pharmacology.
[3] B. Lipworth,et al. Effects of airway calibre on lung delivery of nebulised salbutamol. , 1997, Thorax.
[4] O. Usmani,et al. Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .
[5] Varsha Chavan,et al. Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler , 2008, AAPS PharmSci.
[6] W. Finlay,et al. The effect of breathing pattern on nebulizer drug delivery. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[7] J Bourquin,et al. Application of artificial neural networks (ANN) in the development of solid dosage forms. , 1997, Pharmaceutical development and technology.
[8] M. Svartengren,et al. Deposition of large particles in human lung. , 1987, Experimental lung research.
[9] D. Barlow,et al. Artificial Neural Network Prediction of Aerosol Deposition in Human Lungs , 2002, Pharmaceutical Research.
[10] Raymond C. Rowe,et al. Intelligent Software for Product Formulation , 1998 .
[11] Marcel de Matas,et al. Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks. , 2007, Journal of pharmaceutical sciences.
[12] M. Vahteristo,et al. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[13] K. Amighi,et al. Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation , 2006, Pharmaceutical Research.
[14] K. Saunders,et al. Influence of age on response to ipratropium and salbutamol in asthma. , 1981, Thorax.
[15] R. Suedee,et al. The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. , 2005, Journal of pharmaceutical sciences.
[16] Peter York,et al. Comparison of neurofuzzy logic and neural networks in modelling experimental data of an immediate release tablet formulation. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] J N Pritchard,et al. The influence of lung deposition on clinical response. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[18] D. Barlow,et al. Artificial neural network prediction of the patterns of deposition of polydisperse aerosols within human lungs. , 2005, Journal of pharmaceutical sciences.
[19] H. Bisgaard,et al. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. , 1997, The European respiratory journal.
[20] T. Niu,et al. Familial aggregation of bronchodilator response: a community-based study. , 2000, American journal of respiratory and critical care medicine.
[21] J A Dowell,et al. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. , 1999, Journal of pharmaceutical sciences.
[22] H. Chrystyn,et al. Determination of the Relative Bioavailability of Salbutamol to the Lungs Following Inhalation from Dry Powder Inhaler Formulations Containing Drug Substance Manufactured by Supercritical Fluids and Micronization , 2007, Pharmaceutical Research.
[23] H. Chrystyn,et al. An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[24] J. Lammers,et al. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.
[25] B O Stuart,et al. Deposition of inhaled aerosols. , 1973, Archives of internal medicine.
[26] C. Leach,et al. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[27] Jaber Emami,et al. In vitro - in vivo correlation: from theory to applications. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[28] H. Chrystyn,et al. Standards for Bioequivalence of Inhaled Products , 1994, Clinical pharmacokinetics.
[29] R. Hermann,et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. , 2000, The European respiratory journal.
[30] Y. Cheng,et al. Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.